Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
BEAM Price/Volume Stats
| Current price | $23.90 | 52-week high | $49.50 |
| Prev. close | $24.31 | 52-week low | $16.95 |
| Day low | $23.64 | Volume | 4,505,330 |
| Day high | $24.94 | Avg. volume | 1,398,769 |
| 50-day MA | $32.82 | Dividend yield | N/A |
| 200-day MA | $27.52 | Market Cap | 1.95B |
BEAM Stock Price Chart Interactive Chart >
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall StreetWall Street is uber-bullish on these two Ark Invest holdings. |
11 Most Promising Biotech Stocks to Buy According to AnalystsIn this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […] |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry’s premier autologous cell therapy comp |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
BEAM Price Returns
| 1-mo | -31.46% |
| 3-mo | 0.89% |
| 6-mo | 35.10% |
| 1-year | -20.57% |
| 3-year | -66.37% |
| 5-year | N/A |
| YTD | -12.20% |
| 2023 | -30.40% |
| 2022 | -50.92% |
| 2021 | -2.39% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...